<DOC>
	<DOCNO>NCT00563680</DOCNO>
	<brief_summary>Single-arm , open-label study AMG 479 35 subject Ewing 's Family Tumors ( EFTs ) Desmoplastic Small Round Cell Tumors ( DSRCTs ) progress recur least one prior chemotherapy regimen . An exploratory cohort additional 10 subject prior exposure anti-IGF-1R therapy progress recur least one prior chemotherapy regimen also assess .</brief_summary>
	<brief_title>QUILT-3.025 : A Phase 2 Study AMG 479 Relapsed Refractory Ewing 's Family Tumor Desmoplastic Small Round Cell Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Desmoplastic Small Round Cell Tumor</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female subject ≥ 16 year age diagnosis EFT DSRCT relapse progress least one prior chemotherapeutic regimen eligible study . Before studyspecific procedure , appropriate write informed consent must obtain . Disease Related Subjects pathological histological diagnosis Ewing 's Family Tumor Desmoplastic Small Round Cell Tumor . Measurable disease define RECIST . Documented failure least one prior chemotherapy regimen disease . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 . Demographic Males female ≥ 16 year old . Signed write informed consent . Able comply visit procedure . Laboratory Willing provide exist and/or newly acquire tumor sample . Diabetic Subjects ( Type 1 2 ) must HgbA1c &lt; 8.0 % fast blood glucose level &lt; 160 mg/dL . General Must willing able use birth control ( double barrier protection abstinence ) 6 month study Prior exposure another antiIGF1R therapy allow limited number additional subject ( 10 ) exploratory cohort Exclusion Criteria Disease Related Known brain metastasis . History bleed diathesis . History another malignancy . History chronic hepatitis . Documented prior history human immunodeficiency virus . Laboratory Absolute neutrophil count &lt; 1.5 x109/L . Platelet count &lt; 100 x 109/L . Hemoglobin &lt; 9 g/dL . PT &gt; 1.5 x institutional upper limit normal ( IULN ) PTT &gt; 1.0 x IULN . Serum creatinine &gt; 1.5 x IULN . Aspartate aminotransferase ( AST ) &gt; 2.5 x IULN Alanine aminotransferase ( ALT ) &gt; 2.5 x IULN ( &gt; 5.0 x liver metastasis present ) . Total bilirubin &gt; 1.5 IULN ( &gt; 3.0 x document Gilbert 's Syndrome ) Medication Antitumor treatment within 21 day Study Day 1 . Anticoagulation therapy within 28 day Study Day 1 . Major surgery within 28 day Study Day 1 . General Other investigational procedure exclude . Inability tolerate intravenous administration . Subject pregnant ( eg , positive HCG test ) breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>AMG 479</keyword>
	<keyword>IGF-1R</keyword>
	<keyword>Insulin-like growth factor</keyword>
	<keyword>Insulin-like growth factor receptor</keyword>
	<keyword>Ewing 's</keyword>
	<keyword>Sarcoma</keyword>
</DOC>